argenx, Bayer, Boehringer Ingelheim, Genentech, Gilead, GSK, Merck, Novo Nordisk, Takeda, and Vertex share how they are redefining engagement across sales, marketing, and medical

PLEASANTON, Calif., May 14, 2026 /PRNewswire/ — Veeva Systems (NYSE: VEEV) will showcase the future of agentic commercial in biopharma at Veeva Commercial Summit, May 19-20 in Boston. Leaders from argenx, Bayer, Boehringer Ingelheim, Genentech, Gilead, GSK, Merck, Novo Nordisk, Takeda, Vertex, and more will share AI successes and explore new approaches to commercial engagement.

Veeva will highlight its vision for Agentic Commercial, bringing together industry-specific AI, data, and applications to help the industry advance and deliver better medicine to more patients. Organizations ranging from top 20 biopharmas to emerging biotechs will share how they are leveraging new strategies, technologies, and insights to improve engagement and deliver measurable value.

More than 100 sessions at Summit will highlight what’s new in Commercial Cloud and Data Cloud, and customer successes, including:

Accelerating Agentic Commercial at scale

Genentech, Gilead, and Novo Nordisk advancing innovation with next-generation CRMGSK’s vision for shaping customer engagement with Vault CRM and Veeva AIAvidity Biosciences, A Novartis Company, and Boehringer Ingelheim’s agentic content strategy for faster quality reviewsBoehringer Ingelheim and Gilead giving doctors and patients instant, compliant answers

Precision data powering AI, faster insights, actions, and launch success

Merck and Takeda integrating deep data to drive business processes and AIMoonLake and Unicycive using modern data to quickly identify and engage patientsargenx’s media measurement framework for its DTC launch strategy

Medical driving impact and improved patient outcomes

GSK and Vertex establishing a modern operating system for medical affairsAstellas, Bayer, and Chiesi USA capturing and sharing medical insights to drive action

With more than 2,000 industry professionals, Veeva Commercial Summit is the largest commercial and medical event in North America. More than 40 sponsoring partners include Accenture, Conexus, Cognizant, EY, IQVIA, and Slipstream. The event is open exclusively to life sciences professionals who can register at veeva.com/Summit.

About Veeva Systems
Veeva delivers the industry cloud for life sciences with software, AI, data, and consulting. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,500 customers, ranging from the world’s largest pharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com.

Veeva Forward-Looking Statements
This release contains forward-looking statements regarding Veeva’s products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-K for the fiscal year ended January 31, 2026, which you can find here (a summary of risks which may impact our business can be found on pages 13 and 14), and in our subsequent SEC filings, which you can access at sec.gov.

Contact:
Maria Scurry
Veeva Systems
maria.scurry@veeva.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/veeva-commercial-summit-to-feature-biopharmas-ai-successes-and-the-path-to-agentic-commercial-302771854.html

SOURCE Veeva Systems

NEW YORK, May 14, 2026 /PRNewswire/ — As Memorial Day approaches, Monport Laser is recognizing the holiday with a campaign that highlights craftsmanship, creativity, and appreciation for the people who continue to build and create across industries. The Memorial Day promotion introduces limited-time savings on a wide range of laser machines designed for hobbyists, entrepreneurs, and professional workshops.

Businesses across industries such as signage, woodworking, jewelry, metal fabrication, personalized gifts, and product manufacturing are investing in laser machines to improve production speed, precision, and customization capabilities. The growing popularity of custom-made products and short-run production has also encouraged more entrepreneurs and workshops to adopt laser engraving systems for daily operations.

From engraved tumblers and acrylic signs to branded packaging and industrial metal marking, laser engraving technology is becoming an essential production tool for businesses of all sizes.

As the industry expands, demand continues rising for equipment such as the CO2 laser engraver, fiber laser engraving machine, and desktop CO2 laser machine. Compact systems are becoming increasingly popular among startups, home-based businesses, and creative studios, while larger industrial machines are helping manufacturers scale production with greater efficiency.

At the same time, more businesses are seeking portable laser engraver solutions that provide flexibility for smaller workspaces and mobile production setups. Industrial manufacturers are also adopting high power laser engraver systems capable of handling large-scale engraving and cutting projects with consistent precision.

“Laser engraving technology is no longer limited to industrial factories,” said Monport  Laser CEO. “Today, small businesses, creators, and manufacturers are using laser systems to produce customized products faster and more efficiently while maintaining professional-quality results.”

Monport Laser continues expanding its product lineup to support both entry-level users and commercial production businesses. The company’s offerings include the GT Series, GM Pro Series and GA Series fiber laser machines for metal engraving applications, along with the Mega S, Reno Series, and Effi Series CO2 laser machines for engraving and cutting materials such as wood, acrylic, leather, rubber, and glass.

The GT Series fiber laser machine is designed for industrial metal engraving and high-speed marking applications. The lineup includes 30W and 50W Split Fiber Laser models, as well as 60W, 80W, 100W, and 200W Split MOPA Fiber Laser systems. These machines are commonly used for deep engraving, color marking on stainless steel, batch production, and detailed industrial applications requiring precision and power.

Monport’s GM Pro Series fiber laser engraver focuses on compact and integrated fiber laser solutions for workshops, small businesses, and creators looking for efficient metal engraving equipment. The series includes 20W, 30W, and 50W Integrated Fiber Laser models, along with 30W and 60W JPT MOPA Fiber Laser systems designed for enhanced engraving flexibility and detailed marking performance across different metal materials.

The GA Series fiber laser features advanced MOPA fiber laser technology for users seeking high-performance engraving and marking capabilities. Available in 60W and 100W configurations, the GA Series supports precision metal engraving, color marking, and industrial customization applications while maintaining stable production efficiency for commercial environments.

For CO2 laser engraving and cutting, Monport offers the Reno Series desktop CO2 laser, which includes 45W and 65W models along with PRO and Pro Vision editions. These laser machines are built for creators and businesses working with non-metal materials such as wood, acrylic, leather, and rubber. The Reno Pro Vision systems also integrate enhanced workflow and viewing features designed to improve engraving accuracy and ease of operation.

The Monport Mega S serves as the upgraded version of Monport’s Mega platform, offering improved functionality, workspace efficiency, and production performance for users seeking a desktop CO2 laser machine with expanded creative capabilities. The system is designed for small workshops, custom product businesses, and creators looking for professional engraving results in a compact setup.

Monport’s Effi Series high-power laser engraver is built for higher-output engraving and cutting applications requiring increased speed and production capacity. The lineup includes the Effis9s 90W, Effis10s 100W, Effis13s 130W, and Effis16s 150W models. These CO2 laser machines are commonly used for large-format engraving, batch production, signage manufacturing, and advanced fabrication projects.

Monport has also expanded into UV laser technology with its with its 6W and 10W UV laser engravers designed for cold marking applications. These laser machines allow users to engrave heat-sensitive materials with greater precision while minimizing burn marks and material damage.

The company’s fiber laser engraving machine models are commonly used for metal marking, jewelry engraving, and industrial applications, while its desktop CO2 laser machine systems are widely used by creators, schools, workshops, and small businesses looking for compact production equipment.

To support businesses investing in laser technology, Monport is launching a limited-time Memorial Day promotion featuring tiered discounts and complimentary accessories on select machines.

The Memorial Day offers include:

Savings ranging from $40 to $390 based on purchase amountComplimentary accessories with select CO2 and fiber laser systemsFree engraving and workflow software with eligible machinesA free 6W handheld diode laser engraver with select models

The promotion includes several of Monport’s popular laser machines designed for engraving, cutting, and production applications across multiple industries.

As laser engraving technology continues becoming more accessible, industry demand is expected to keep growing among businesses focused on customization, faster turnaround times, and scalable production solutions.

The Memorial Day promotion is available for a limited time through Monport’s official website.

To learn more about Monport’s Memorial Day event and available laser engraving systems, visit Monport Laser Official Website

Media Contact:
Monport Laser
Email: official@monportlaser.com 
Website: www.monportlaser.com.

View original content:https://www.prnewswire.com/news-releases/monport-marks-memorial-day-with-savings-on-laser-engraving-machines-and-creative-tools-302772294.html

SOURCE Monport Laser

CAMBRIDGE, Mass., May 14, 2026 /PRNewswire/ — Cypherpunk Technologies Inc., (Nasdaq: CYPH) (“Cypherpunk”), today reported financial results for the first quarter ended March 31, 2026.

“Since the start of 2026, Cypherpunk has advanced the mission to become a leading privacy technology company with a digital asset treasury strategy focused on Zcash by making our first privacy technology investment and increasing our treasury holdings to 314,185.70 ZEC,” said Douglas E. Onsi, President and CEO of Cypherpunk Technologies. “At AACR 2026, our Leap Therapeutics subsidiary presented a new DKK1 biomarker assay developed to support the selection of patients likely to benefit from sirexatamab therapy, along with the positive outcomes from our DeFianCe colorectal cancer study generated in patients with high DKK1 levels. In addition, sirexatamab received Fast Track designation from the FDA in May 2026.”

“Privacy-protecting assets and related technologies will be critical in the increasingly digital and AI driven world. Our $5 million investment in Zcash Open Development Labs (ZODL), the core developers of the Zcash Network and Zodl, the leading Zcash wallet, reflects our commitment to supporting the Zcash ecosystem and to building innovative companies that make the promise of private digital money a reality,” said Will McEvoy, Chief Investment Officer of Cypherpunk.

Cypherpunk Highlights:

Increased Zcash treasury holdings to 314,185.70 ZECFrom the last update on April 15, 2026 through May 13, 2026, Cypherpunk purchased an additional 10,279.30 ZEC for $5 million at an average purchase price of $486.41 per ZEC.As of May 13, 2026, Cypherpunk held a total of 314,185.70 ZEC at an average purchase price of $337.86, representing approximately 1.88% of the total circulating supply of the Zcash network.ZEC is a digital currency that can be transmitted over a peer-to-peer payment system. Zcash uses a cryptographic method called “zero-knowledge proofs” to allow users to engage in financial transactions while maintaining greater privacy.Invested $5 million into Zcash Open Development Labs (ZODL)In March 2026, Cypherpunk expanded its holdings with a $5 million investment in ZODL, alongside key investors including a16z, Winklevoss Capital, Coinbase, Paradigm, Chapter One, David Friedberg, Balaji Srinivasan, and others. This marked Cypherpunk’s first technology investment outside of ZEC. ZODL, which houses the top Zcash wallet, Zodl, aims to make Zcash easier to use with continued development of the wallet and support of the Zcash protocol.Launched new website and investor dashboard at cypherpunk.comThe Company launched its new website and investor dashboard at cypherpunk.com. The dashboard provides shareholders with direct visibility into the Company’s key metrics, ZEC holdings, other privacy investments, and Zcash network metrics.

Leap Therapeutics Subsidiary Highlights:

Sirexatamab received Fast Track designation from FDAIn May 2026, the U.S. Food and Drug Administration (FDA) granted Fast Track designation to sirexatmab in combination with fluoropyrimidine plus oxaliplatin- or irinotecan-based chemotherapy and bevacizumab, for the treatment of patients with DKK1-high metastatic colorectal cancer whose disease has progressed following one prior systemic therapy.The Fast Track program is intended to facilitate the development and expedite the review of drug candidates and vaccines that treat serious conditions and fill an unmet medical need. Programs with Fast Track designation may benefit from frequent communication with the FDA, in addition to a rolling submission of the marketing application.Presented new plasma DKK1 biomarker assay and results based on Part B of the DeFianCe study of sirexatamab plus bevacizumab and chemotherapy in colorectal cancer (“CRC”) patients at the American Association for Cancer Research (AACR) 2026:At AACR 2026 in April, the Company presented a new plasma DKK1 biomarker assay that could be used as a companion diagnostic to select patients who would benefit from treatment with sirexatamab, the Company’s anti-DKK1 monoclonal antibody.The new plasma DKK1 biomarker assay was used to test the patient samples from Part B of the DeFianCe study, a Phase 2 study of sirexatamab in combination with bevacizumab and chemotherapy compared to bevacizumab and chemotherapy in patients with microsatellite stable CRC who have received one prior systemic therapy for advanced disease.Sirexatamab demonstrated a statistically significant benefit on overall response rate (“ORR”) and overall survival (“OS”) in patients with high levels of DKK1 using the new plasma DKK1 biomarker assay.50% of patients had DKK1-high levels > 380 pg/ml, and in this subgroup of patients (n=87):ORR was 42% (including one complete response) in the Sirexatamab Arm vs. 16% ORR in the Control Arm, p-value = 0.003.mOS was not reached in the Sirexatamab Arm vs. 14.39 months in the Control Arm, HR 0.47, p-value = 0.0244.DKK1 plasma levels from patients in the DeFianCe study were similar to commercially acquired CRC patient samples.

Selected First Quarter 2026 Financial Results

Net loss was $77.2 million for the first quarter 2026, compared to $15.4 million for the first quarter of 2025. The increase was primarily due to unrealized losses on the fair value of the Company’s ZEC treasury holdings which are marked to market at the end of each period. During the first quarter of 2026, the price of ZEC declined from $508.09 to $240.47.

Research and development expenses were $0.2 million for the three months ended March 31, 2026, compared to $12.9 million for the same period in 2025. The decrease for the three months ended March 31, 2026 was primarily due to a decrease in clinical trial costs and manufacturing costs due to the completion of our clinical trials.

General and administrative expenses were $4.7 million for the three months ended March 31, 2026, compared to $3.0 million for the same period in 2025. The increase for the three months ended March 31, 2026 was primarily due to an increase in stock-based compensation expense due to RSUs granted to employees and directors.

During the three months ended March 31, 2026, the Company recorded a $77.6 million unrealized loss on the change in fair value of the Company’s ZEC treasury holdings as the price of ZEC declined during the first quarter of 2026 from $508.09 to $240.47.

Cash and cash equivalents totaled $6.7 million on March 31, 2026, and ZEC treasury holdings, categorized as digital asset receivable, totaled $73.8 million based on the ZEC price of $240.47 on March 31, 2026.

About Cypherpunk

Cypherpunk Technologies is a privacy technology company. The Company’s mission is to advance technologies that guarantee privacy for humans on the internet. Cypherpunk pursues this mission through two primary strategies: accumulating Zcash (ZEC); and investing in, acquiring, and building technologies that push the frontier of privacy forward. Additionally, through its subsidiary Leap Therapeutics, the Company is developing novel therapies for patients with cancer, continuing the development of sirexatamab and FL-501. For more information about the Company, visit our websites at http://www.cypherpunk.com and http://www.leaptx.com or view our public filings with the SEC that are available via EDGAR at http://www.sec.gov.

About Winklevoss Capital

Winklevoss Capital is an investment firm founded in 2012 by Cameron and Tyler Winklevoss that invests in frontier technologies.

FORWARD-LOOKING STATEMENTS

This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements generally can be identified by the use of words such as “anticipate,” “expect,” “plan,” “could,” “may,” “will,” “believe,” “estimate,” “forecast,” “goal,” “project,” and other words of similar meaning. Forward-looking statements address various matters including statements relating to the value of the Company’s ZEC holdings, the investment in ZODL, or digital assets held or to be held by the Company, the expected future market, price, and liquidity of ZEC or other digital assets the Company acquires, the macro and political conditions surrounding Zcash or digital assets, the Company’s plan for value creation and strategic advantages, market size and growth opportunities, regulatory conditions, competitive position and the interest of other corporations in similar business strategies, technological and market trends, and future financial condition and performance. Risks and uncertainties of the digital asset treasury strategy include, among others: (a) risks relating to the Company’s operations and business, including the highly volatile nature of the price of ZEC; (b) the risk that material changes in the price of ZEC, such as decreases in price, will result in significant changes to the Company’s financial statements, such as unrealized losses on fair value of ZEC holdings and net loss; (c) the risk that the price of the Company’s Common Stock may be highly correlated to the price of ZEC; (d) the risk that the Company will fail to realize the anticipated benefits of the ZEC digital asset treasury strategy or the investment in ZODL; (e) risks related to the custody of our ZEC and our reliance on Gemini Space Station and its affiliates for trading and custody services; (f) changes in business, market, financial, political and regulatory conditions; (g) risks related to increased competition in the industries in which the Company does and will operate; (h) risks relating to significant legal, commercial, regulatory and technical uncertainty regarding digital assets generally; (i) risks relating to the treatment of crypto assets for U.S. and foreign tax purposes; and (j) the ability to comply with the continued listing requirements of the Nasdaq Capital Market. With respect to our biotechnology operations, important factors that could cause actual results to differ materially from our plans, estimates or expectations could include, but are not limited to: (i) our ability and plan to develop and commercialize sirexatamab; (ii) our estimates regarding our capital requirements and our ability to raise additional financing to support continued development; (iii) the success of other competing therapies that may become available; (iv) the manufacturing capacity for sirexatmab; and (v) our ability to maintain and protect our intellectual property rights.

New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. The Company may not actually achieve the forecasts disclosed in such forward-looking statements, and you should not place undue reliance on such forward-looking statements. Such forward-looking statements are subject to a number of material risks and uncertainties including but not limited to those set forth under the caption “Risk Factors” in the Company’s most recent Annual Report on Form 10-K filed with the SEC, or as may be included in other reports or information we file with the SEC, as well as discussions of potential risks, uncertainties, and other important factors in its subsequent filings with the SEC. Any forward-looking statement speaks only as of the date on which it was made. Neither the Company, nor any of its affiliates, advisors or representatives, undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date hereof.

CONTACT:
Douglas E. Onsi
President & Chief Executive Officer
Cypherpunk Technologies Inc.
617-714-0360

For Investors:

Matthew DeYoung
Investor Relations
Argot Partners
212-600-1902
leap@argotpartners.com

For Media:

Jacqueline Ortiz Ramsey
It Factor Strategies
954-294-3249
jacqueline@itfactorstrategies.com

View original content:https://www.prnewswire.com/apac/news-releases/cypherpunk-technologies-reports-first-quarter-2026-financial-results-302771706.html

SOURCE Cypherpunk Technologies Inc.